$4.8086
0.1086[2.31%]
At close: Apr 19
$4.8086
0[0.00%]
After Hours: 5:25PM EDT
Vistagen Therapeutics
(NASDAQ:VTGN)Vistagen Therapeutics Stock (NASDAQ:VTGN), Analyst Ratings, Price Targets, Predictions
Vistagen Therapeutics Inc has a consensus price target of $13.2, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Jefferies, Stifel, and Maxim Group on December 7, 2023, November 14, 2023, and September 5, 2023. With an average price target of $19 between Jefferies, Stifel, and Maxim Group, there's an implied 295.13% upside for Vistagen Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Stifel
Maxim Group
William Blair
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Vistagen Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/07/2023 | VTGN | Buy Now | Vistagen Therapeutics | $4.81 | 211.94% | Jefferies | Andrew Tsai | $0.2 → $15 | Upgrade | Hold → Buy | Get Alert |
| 11/14/2023 | VTGN | Buy Now | Vistagen Therapeutics | $4.81 | 149.55% | Stifel | Paul Matteis | → $12 | Initiates | → Buy | Get Alert |
| 09/05/2023 | VTGN | Buy Now | Vistagen Therapeutics | $4.81 | 523.88% | Maxim Group | Jason McCarthy | $30 → $30 | Maintains | Buy | Get Alert |
| 08/07/2023 | VTGN | Buy Now | Vistagen Therapeutics | $4.81 | 523.88% | Maxim Group | Jason McCarthy | → $30 | Upgrade | Hold → Buy | Get Alert |
| 07/26/2022 | VTGN | Buy Now | VistaGen Therapeutics | $4.81 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 07/22/2022 | VTGN | Buy Now | VistaGen Therapeutics | $4.81 | — | William Blair | Tim Lugo | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/20/2021 | VTGN | Buy Now | VistaGen Therapeutics | $4.81 | 87.16% | Baird | Brian Skorney | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Vistagen Therapeutics (VTGN)?
The latest price target for Vistagen Therapeutics (NASDAQ: VTGN) was reported by Jefferies on December 7, 2023. The analyst firm set a price target for $15.00 expecting VTGN to rise to within 12 months (a possible 211.94% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vistagen Therapeutics (VTGN)?
The latest analyst rating for Vistagen Therapeutics (NASDAQ: VTGN) was provided by Jefferies, and Vistagen Therapeutics upgraded their buy rating.
When was the last upgrade for Vistagen Therapeutics (VTGN)?
The last upgrade for Vistagen Therapeutics Inc happened on December 7, 2023 when Jefferies raised their price target to $15. Jefferies previously had a hold for Vistagen Therapeutics Inc.
When was the last downgrade for Vistagen Therapeutics (VTGN)?
The last downgrade for Vistagen Therapeutics Inc happened on July 26, 2022 when Maxim Group changed their price target from N/A to N/A for Vistagen Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Vistagen Therapeutics (VTGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on December 7, 2023 so you should expect the next rating to be made available sometime around December 7, 2024.
Is the Analyst Rating Vistagen Therapeutics (VTGN) correct?
While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a upgraded with a price target of $0.20 to $15.00. The current price Vistagen Therapeutics (VTGN) is trading at is $4.81, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.